Skip to main content
Clinical Trials/ACTRN12613000165785
ACTRN12613000165785
Completed
Phase 3

A single-blinded randomised controlled trial to determine the effect of topical application of Calendula officinalis based lotion on the prevalence of clinically significant radiation induced dermatitis in women undergoing radiotherapy for breast cancer.

Dr Michael Penniment0 sites178 target enrollmentFebruary 11, 2013

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Radiation induced dermatitis
Sponsor
Dr Michael Penniment
Enrollment
178
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 11, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Dr Michael Penniment

Eligibility Criteria

Inclusion Criteria

  • Women who have undergone lumpectomy or mastectomy and are due to undergo post\-surgical radiotherapy for
  • breast cancer using standard treatment pathways
  • No concurrent chemotherapy
  • Informed consent

Exclusion Criteria

  • Known allergy to calendula/officinalis or sorbolene
  • Salicylate sensitivity
  • Previous radiation to breast
  • History of skin/dermatitis condition
  • On anticoagulant therapy
  • Pregnant or breast feeding
  • Reaction to skin test

Outcomes

Primary Outcomes

Not specified

Similar Trials